S. Gillard

Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs

C. Fidler, Torsten Elmelund Christensen, S. Gillard, 2011, Journal of medical economics.

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

S. Gillard, M. Spino, F. Tricta, 2013, PharmacoEconomics.

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

S. Gillard, M. Spino, F. Tricta, 2013, PharmacoEconomics.

Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice

C. Fidler, S. Gillard, G. Montalescot, 2010, Advances in therapy.

Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care

S. Gillard, A. Finlay, Andrew Yule Finlay, 2005, International journal of clinical practice.

In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

S. Gillard, R. Wasiak, G. Trew, 2010, Reproductive biology and endocrinology : RB&E.

Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity.

S. Gillard, J. Warner, A. Ward, 2005, Journal of rehabilitation medicine.